InCROM Group's current success has been achieved by the unique approach in the way employees conduct themselves, working to ensure that, in all tasks, business ethics and science co-exist equally, leading to the development of our global motto:


InCROM Europe, an owned subsidiary of InCROM Group, was the first exclusive Japanese CRO in the UK. It has worked with most of the top 20 pharmaceutical companies and has conducted the highest number of 1st generation Japanese studies outside of Japan. Thus far Japanese bridging PK studies have been accomplished in collaboration with leading local CROs.

InCROM Europe is proud to announce the addition of the London based InCROM Clinical Research Unit (ICRU). Our InCROM experienced clinical team has been transferred to the custom designed facility located in the heart of London, thereby creating a full service CRO.

The modern, purpose built 30-bed facility includes an on-site 6-bed Level 3 intensive care unit. Highly experienced staff work within ICRU as dedicated project teams, utilizing a wide range of modern, innovative, advanced equipment and procedures to ensure enhanced drug development. Together with our principal investigator, InCROM Europe capitalizes on the wealth of experience gained from over 330 clinical trials guaranteeing the highest standards and quality, which will benefit any clinical trial.